Presentation is loading. Please wait.

Presentation is loading. Please wait.

Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial.

Published byPhyllis Wright Modified over 6 years ago

Similar presentations

Presentation on theme: "Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial."— Presentation transcript:

1 Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial.
Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial. FEV1 was measured at different points for the noninvasive intermittent positive pressure ventilation (NIPPV) + rehabilitation group (red triangles) and the rehabilitation group (blue squares). The change was significantly better in the NIPPV + rehabilitation group (p<0.02). Reproduced from [33] with permission from the publisher. Marieke L. Duiverman ERJ Open Res 2018;4: ©2018 by European Respiratory Society

Download ppt "Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial."

Similar presentations

Evolution of ventilatory settings in randomised controlled trials investigating noninvasive ventilation in stable or post-exacerbation chronic obstructive.

Evolution of ventilatory settings in randomised controlled trials investigating noninvasive ventilation in stable or post-exacerbation chronic obstructive.
Examples of computerised incentives used in spirometry

Examples of computerised incentives used in spirometry
Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.

Least squares (LS) mean change from baseline (95% CI) in trough forced expiratory volume in 1 s (FEV1) according to chronic obstructive pulmonary disease.
The influence of noninvasive ventilation (NIV) on the delicate balance between increased load and decreased capacity of the respiratory system in severe.

The influence of noninvasive ventilation (NIV) on the delicate balance between increased load and decreased capacity of the respiratory system in severe.
Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)

Correlation of excessive reactive oxygen species (ROS) production to clinical disease severity. Correlation of excessive reactive oxygen species (ROS)
The EASI model structured around four modules (exposure (top left), activity (bottom left), severity (top right) and impact (bottom right)), each of which.

The EASI model structured around four modules (exposure (top left), activity (bottom left), severity (top right) and impact (bottom right)), each of which.
Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.

Summary findings regarding the efficacy/safety profile across xanthines in chronic obstructive pulmonary disease patients. a) Combined plot of the change.
Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.

Relationship between the change in a) ventilatory and b) cerebrovascular responses in older healthy subjects (Older) and chronic obstructive pulmonary.
Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.

Change from baseline in trough forced expiratory volume in 1 s (FEV1) (per-protocol population). Change from baseline in trough forced expiratory volume.
Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %

Distribution of forced expiratory volume in 1 s (FEV1) relative to Global Lung Function Initiative reference values (GLI2012) [10] expressed as FEV1 %
The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.

The values for the provoking dose of mannitol to cause a 15% decrease (PD15) in forced expiratory volume in 1 s (FEV1) showing the different levels of.
Survival without tracheostomy

Survival without tracheostomy
Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.

Immunostaining for lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) adduct in the lungs of smokers with and without chronic obstructive pulmonary.
A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.

A) Exhaled nitric oxide fraction (FeNO) before and after 9 weeks of treatment; b) percentage change in forced expiratory volume in 1 s (FEV1) following.
Results from a recent bench test of 13 noninvasive ventilators using a computer-controlled active patient simulator. a) Proportion of the preset tidal.

Results from a recent bench test of 13 noninvasive ventilators using a computer-controlled active patient simulator. a) Proportion of the preset tidal.
A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.

A) Forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio as a function of age showing individuals with FEV1/FVC ratio less than the.
Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.

Change from baseline following beclomethasone/formoterol and placebo in a) platelet–monocyte aggregate formation, b) P-selectin expression and c) platelet.
A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p

A) In the presence of Aspergillus fumigatus, local IgA and IgG levels to A. fumigatus are significantly elevated; *: p
A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.

A) Peak forced expiratory volume in 1 s within 3 h post-dosing (peak FEV10–3h) response following once-daily tiotropium Respimat add-on to medium-dose.
Response to two identical exercise tests (T1 and T2) in 278 adults and 95 children with signs and symptoms of asthma but no definite diagnosis. Response.

Response to two identical exercise tests (T1 and T2) in 278 adults and 95 children with signs and symptoms of asthma but no definite diagnosis. Response.

Similar presentations

Ads by Google